Thursday, November 30, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Hematology/Oncology Fellow
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Professor
Medical School Hannover
Hannover, Germany
Associate Professor, Medicine
College of Medicine Tucson
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
Associate Dean, Clinical and Translational Research
The University of Arizona Health Sciences
Tucson, Arizona, United States
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This activity is intended for oncologists, gastroenterologists, pathologists, and other healthcare providers caring for patients with cholangiocarcinoma (CCA)
The goal of this activity is for learners to better understand biomarker testing in patients with CCA, mechanisms of action (MOAs) of emerging treatment pathways, and the efficacy and safety of new agents.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Hematology/Oncology Fellow
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Professor
Medical School Hannover
Hannover, Germany
Associate Professor, Medicine
College of Medicine Tucson
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
Associate Dean, Clinical and Translational Research
The University of Arizona Health Sciences
Tucson, Arizona, United States
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 1.0
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 3/11/2022
Valid for credit through: 3/11/2023, 11:59 PM EST
processing....
All sections of this activity are required for credit.
The goal of this activity is for learners to better understand biomarker testing in patients with CCA, mechanisms of action (MOAs) of emerging treatment pathways, and the efficacy and safety of new agents.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
